Division of PerkinElmer Inc.
Latest From ViaCell Neuroscience
Aegerion Pharmaceuticals, a US-based biopharmaceutical company focused on the development and commercialisation of therapeutics to treat severe lipid disorders, has appointed Marc Beer as both CEO and a member of the board of directors. He has more than 20 years experience in biotechnology, pharmaceuticals and diagnostics. In 2000, he became the founding CEO of ViaCell, a biotech company specialising in the collection and preservation of umbilical cord blood stem cells. Mr Beer has also worked for Genzyme and Abbott Laboratories.
Seaside Therapeutics (US) has appointed Marc Beer, former CEO of ViaCell, Karen Dawes, president of Knowledge Decisions, and Dr Steven Paul, former executive vice-president for science and technology at Lilly, to its board of directors. They join Seaside's current board members – the company's president & CEO, Dr Randall Carpenter, and Peter Whipp, managing director of Barony Trust, Seaside's largest investor. Seaside is creating treatments to correct or improve the course of fragile X syndrome, autism and other neurodevelopmental disorders.
John Thero has joined Amarin (Ireland) as chief financial officer. He has more than 20 years' senior financial and operational management experience, having previously served as CFO at ViaCell and Abiomed.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Neurology, Nervous System
- Cerebrotec Inc.
- North America
- Parent & Subsidiaries
- PerkinElmer Inc.
- Senior Management
Marc D Beer, Chmn. & CEO
Jeff Sacher, CFO
Christoph M Adams, PhD, SVP, Bus. Dev.
Kurt C Gunter, MD, SVP, Clinical & Reg. Affairs
- Contact Info
Phone: (866) 842-2355
131 Clarendon St.
Boston, MA 02116
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.